



DATE: 14.02.2025

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Tower,  
Dalal Street, Mumbai-400001

Script Code: 539206

Symbol: GVBL

**Subject: Outcome of the Board Meeting pursuant to Regulation 30 held today i.e. 14th February, 2025 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

This is to inform you that pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the Board of Directors of the Company at their meeting held on today **Friday, 14th February, 2025**, at the Registered Office of the Company inter-alia to transact the following business items with the permission of the Chair, if any:

1. Considered and approved the standalone Un-Audited financial results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2024. A copy of the said standalone un-audited financial results along with the Limited review report from statutory auditor is enclosed herewith.

The meeting of the Board of Directors commenced at 4:30 PM. and concluded at 5:40 PM.

This is for your information and record.

Thanking you,  
Yours Faithfully,

For and on behalf of  
Genomic Valley Biotech Limited

Yogesh Agrawal  
Managing Director  
DIN: 01165288  
Place: Delhi

**ANDROS & CO.**



**Chartered Accountants**

**901 , 9<sup>th</sup> floor , Tower 1  
Pearls Omaxe , Plot B-1  
Netaji Subhash Place (NSP) ,  
Pitampura , New Delhi 110034  
Email: cabhavukgarg@gmail.com  
Phone : 47060901 , 9560438787**

**LIMITED REVIEW REPORT**

To

the Board of Directors

**Genomic Valley Biotech Limited**

4 K.M.Stone, Berri Chharra Road

Vill. Kherka, Musalman, P.O. Tandaheri Teh Bahadu , Jhajjar,

Haryana – 124507

**1. Introduction**

We have reviewed the accompanying statement of unaudited financial results of **Genomic Valley Biotech Limited** ("the Company") for the quarter and year-to-date period ended **December 31, 2024** ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the **SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015** as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the **Indian Accounting Standard 34 ('Ind AS 34')**, '**Interim Financial Reporting**', prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.



## 2. Scope of Review

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, '**Review of Interim Financial Information Performed by the Independent Auditor of the Entity**', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.


A review is substantially less in scope than an audit conducted in accordance with **Standards on Auditing (SAs)** and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## 3. Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Andros & Co.**

Chartered Accountants,  
FRN No.: 0008976N



CA Bhavuk Garg  
Partner  
Membership No. 502310  
Place: New Delhi  
Date : 14.02.2025



25502310- BMGTZN-2190

**GENOMIC VALLEY BIOTECH LIMITED**  
**Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,**  
**TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507**  
**CIN: L01122HR1994PLC033029**

Genomic Valley Biotech Limited today reported its financial performance for the quarter and nine months ended  
31 December 2024

Highlights of the Un-Audited Financial Results as compared to the previous year are:

In Rs.

Sr. No.	Particular	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous period ended	Previous year ended
		31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Revenue From Operations	22,00,950	20,50,000	3,90,000	58,04,300	16,50,750	16,50,750
II	Other Income	4,308	72,187	-	76,495	15,002	15,003
III	<b>Total Revenue (I+II)</b>	<b>22,05,258</b>	<b>21,22,187</b>	<b>3,90,000</b>	<b>58,80,795</b>	<b>16,65,752</b>	<b>16,65,753</b>
IV	<b>Expenses</b>						
	Cost of materials consumed	-	-	-	-	-	-
	Purchases of Stock-in-Trade	-	-	-	-	-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
	Employee benefits expense	3,20,645	3,54,000	45,000	7,94,645	3,30,000	3,75,000
	Financial costs	-	-	-	-	-	-
	Depreciation and amortization expense	5,000	10,000	2,731	15,000	8,193	10,925
	Other expenses	3,25,857	2,82,550	1,24,702	7,65,854	6,09,748	11,28,348
	<b>Total Expenses (IV)</b>	<b>6,51,502</b>	<b>6,46,550</b>	<b>1,72,433</b>	<b>15,75,499</b>	<b>9,47,941</b>	<b>15,14,273</b>
V	<b>Profit / (Loss) before exceptional item and tax (III-IV)</b>	<b>15,53,756</b>	<b>14,75,637</b>	<b>2,17,567</b>	<b>43,05,297</b>	<b>7,17,811</b>	<b>1,51,480</b>
VI	Exceptional Item	-	-	-	-	-	-
VII	<b>Profit/loss before Tax (V-VI)</b>	<b>15,53,756</b>	<b>14,75,637</b>	<b>2,17,567</b>	<b>43,05,297</b>	<b>7,17,811</b>	<b>1,51,480</b>
VIII	<b>Tax expenses</b>						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	-	-	-	-	-	-339
IX	<b>Profit/ (Loss) for the period from continuing operations (VII-VIII)</b>	<b>15,53,756</b>	<b>14,75,637</b>	<b>2,17,567</b>	<b>43,05,297</b>	<b>7,17,811</b>	<b>1,51,818</b>
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-	-
XII	<b>Profit/ (Loss) from discontinuing operations (after tax) (X-XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Profit/Loss for the period (IX+XII)</b>	<b>15,53,756</b>	<b>14,75,637</b>	<b>2,17,567</b>	<b>43,05,297</b>	<b>7,17,811</b>	<b>1,51,818</b>
XIV	<b>Other Comprehensive Income</b>						
	<b>A (i) Items that will not be reclassified to profit or loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>(ii) Income tax relating to Items that will not be reclassified to profit or loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>B (i) Items that will be reclassified to profit or loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>(ii) Income tax relating to items that will be reclassified to profit or loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)</b>	<b>15,53,756</b>	<b>14,75,637</b>	<b>2,17,567</b>	<b>43,05,297</b>	<b>7,17,811</b>	<b>1,51,818</b>
XVI	<b>Paid up Equity Share Capital, Equity Share of ₹ 10/- each</b>	<b>30,54,500</b>	<b>30,54,500</b>	<b>30,54,500</b>	<b>30,54,500</b>	<b>30,54,500</b>	<b>30,54,500</b>
XVII	<b>Earning Per Equity Share (for continuing operation):</b>						
	1) Basic	0.51	0.48	0.07	1.41	0.24	0.05
	2) Diluted	0.51	0.48	0.07	1.41	0.24	0.05
XVIII	<b>Earning Per Equity Share (for discontinued operation):</b>						
	1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIX	<b>Earning Per Equity Share (for discontinued &amp; continuing operations):</b>						
	1) Basic	0.51	0.48	0.07	1.41	0.24	0.05
	2) Diluted	0.51	0.48	0.07	1.41	0.24	0.05

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on 14.02.2025, The Statutory Auditors of the company have carried out a Limited Review of the Financial Results for these financials.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

For and on behalf of the Board of Genomic Valley Biotech Limited.

  
**Yogesh Agrawal**  
(Managing Director)

DIN-01165288

Add: G-74 Pushkar Enclave  
Paschim Vihar, New Delhi-110063

Place : Delhi  
Dated : 14.02.2025